search
Back to results

Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

Primary Purpose

Leukemia

Status
Completed
Phase
Phase 1
Locations
International
Study Type
Interventional
Intervention
temozolomide
Sponsored by
Children's Oncology Group
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional treatment trial for Leukemia focused on measuring recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, relapsing chronic myelogenous leukemia, childhood acute promyelocytic leukemia (M3), blastic phase chronic myelogenous leukemia

Eligibility Criteria

1 Year - 21 Years (Child, Adult)All SexesDoes not accept healthy volunteers

DISEASE CHARACTERISTICS: Histologically confirmed leukemia of any of the following types: Acute lymphoblastic leukemia Acute myeloid leukemia Chronic myelogenous leukemia in blast crisis Refractory or recurrent disease Immunophenotypic confirmation of disease at initial diagnosis or recurrence More than 25% blasts in the bone marrow (M3) Active extramedullary disease allowed except for leptomeningeal disease No known curative therapy or therapy proven to prolong survival with an acceptable quality of life No active CNS disease PATIENT CHARACTERISTICS: Age 1 to 21 Performance status Karnofsky 50-100% (for patients > 10 years of age) Lansky 50-100% (for patients ≤ 10 years of age) Life expectancy Not specified Hematopoietic WBC < 30,000/mm^3 (hydroxyurea or leukapheresis allowed at the discretion of the principal investigator) Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed) Hemoglobin ≥ 8.0 g/dL (red blood cell transfusions allowed) Hepatic ALT ≤ 5 times upper limit of normal (ULN) Albumin ≥ 2 g/dL Bilirubin ≤ 1.5 times ULN Renal Creatinine normal for age OR Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min/1.73 m^2 Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy At least 7 days since prior biologic therapy, including immunotherapy At least 3 months since prior stem cell transplantation No evidence of active graft-vs-host disease No concurrent biologic therapy No concurrent immunotherapy Chemotherapy Recovered from prior chemotherapy At least 6 weeks since prior nitrosoureas Prior therapy with hydroxyurea allowed for up to 24 hours before initiation of study drug No other concurrent chemotherapy Endocrine therapy Concurrent hydrocortisone or other corticosteroids allowed as premedications prior to blood product transfusions in patients with prior severe allergic reactions Radiotherapy Recovered from prior radiotherapy No concurrent radiotherapy Surgery Not specified Other No other concurrent anticancer agents No other concurrent investigational drugs

Sites / Locations

  • Stanford Cancer Center at Stanford University Medical Center
  • Indiana University Cancer Center
  • Fairview University Medical Center - University Campus
  • Mayo Clinic Cancer Center
  • University of Mississippi Medical Center
  • Herbert Irving Comprehensive Cancer Center at Columbia University
  • SUNY Upstate Medical University Hospital
  • Cincinnati Children's Hospital Medical Center
  • Children's Hospital of Philadelphia
  • Children's Hospital of Pittsburgh
  • St. Jude Children's Research Hospital
  • Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
  • Baylor University Medical Center - Houston
  • Children's Hospital and Regional Medical Center - Seattle
  • Hospital for Sick Children
  • Hopital Sainte Justine

Arms of the Study

Arm 1

Arm Type

Experimental

Arm Label

Temozolomide Therapy

Arm Description

Outcomes

Primary Outcome Measures

Maximum tolerated dose and recommended phase II dose
Toxicity as assessed by CTCAE 3.0
Pharmacokinetics as assessed by CI, area under the curve (AUC), and half-life (T ½)

Secondary Outcome Measures

Antitumor activity
Biologic activity and mechanisms of resistance

Full Information

First Posted
May 14, 2004
Last Updated
February 18, 2014
Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)
search

1. Study Identification

Unique Protocol Identification Number
NCT00083070
Brief Title
Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia
Official Title
A Phase I Trial Of Temozolomide In Pediatric Patients With Refractory/Recurrent Leukemias
Study Type
Interventional

2. Study Status

Record Verification Date
February 2014
Overall Recruitment Status
Completed
Study Start Date
March 2004 (undefined)
Primary Completion Date
September 2004 (Actual)
Study Completion Date
June 2008 (Actual)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Sponsor
Name of the Sponsor
Children's Oncology Group
Collaborators
National Cancer Institute (NCI)

4. Oversight

Data Monitoring Committee
Yes

5. Study Description

Brief Summary
RATIONALE: Drugs used in chemotherapy, such as temozolomide, work in different ways to stop cancer cells from dividing so they stop growing or die. PURPOSE: This phase I trial is studying the side effects and best dose of temozolomide in treating young patients with refractory or recurrent leukemia.
Detailed Description
OBJECTIVES: Primary Determine the maximum tolerated dose and recommended phase II dose of temozolomide in pediatric patients with refractory or recurrent leukemia. Determine the toxic effects of this drug in these patients. Determine the pharmacokinetics of this drug in these patients. Secondary Determine the antitumor activity of this drug in these patients. Determine the biologic activity and mechanism(s) of resistance to this drug in these patients. OUTLINE: This is an open-label, dose-escalation, multicenter study. Patients receive oral temozolomide once daily on days 1-5. Treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. Cohorts of 3-6 patients receive escalating doses of temozolomide until the maximum tolerated dose (MTD) is determined. The MTD is defined as the dose preceding that at which 2 of 6 patients experience dose-limiting toxicity. PROJECTED ACCRUAL: A total of 3-36 patients will be accrued for this study within 18-24 months.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Leukemia
Keywords
recurrent childhood acute lymphoblastic leukemia, recurrent childhood acute myeloid leukemia, relapsing chronic myelogenous leukemia, childhood acute promyelocytic leukemia (M3), blastic phase chronic myelogenous leukemia

7. Study Design

Primary Purpose
Treatment
Study Phase
Phase 1
Interventional Study Model
Single Group Assignment
Masking
None (Open Label)
Allocation
N/A
Enrollment
16 (Actual)

8. Arms, Groups, and Interventions

Arm Title
Temozolomide Therapy
Arm Type
Experimental
Intervention Type
Drug
Intervention Name(s)
temozolomide
Other Intervention Name(s)
Temodar, NSC # 362856
Primary Outcome Measure Information:
Title
Maximum tolerated dose and recommended phase II dose
Title
Toxicity as assessed by CTCAE 3.0
Title
Pharmacokinetics as assessed by CI, area under the curve (AUC), and half-life (T ½)
Secondary Outcome Measure Information:
Title
Antitumor activity
Title
Biologic activity and mechanisms of resistance

10. Eligibility

Sex
All
Minimum Age & Unit of Time
1 Year
Maximum Age & Unit of Time
21 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
DISEASE CHARACTERISTICS: Histologically confirmed leukemia of any of the following types: Acute lymphoblastic leukemia Acute myeloid leukemia Chronic myelogenous leukemia in blast crisis Refractory or recurrent disease Immunophenotypic confirmation of disease at initial diagnosis or recurrence More than 25% blasts in the bone marrow (M3) Active extramedullary disease allowed except for leptomeningeal disease No known curative therapy or therapy proven to prolong survival with an acceptable quality of life No active CNS disease PATIENT CHARACTERISTICS: Age 1 to 21 Performance status Karnofsky 50-100% (for patients > 10 years of age) Lansky 50-100% (for patients ≤ 10 years of age) Life expectancy Not specified Hematopoietic WBC < 30,000/mm^3 (hydroxyurea or leukapheresis allowed at the discretion of the principal investigator) Platelet count ≥ 20,000/mm^3 (platelet transfusions allowed) Hemoglobin ≥ 8.0 g/dL (red blood cell transfusions allowed) Hepatic ALT ≤ 5 times upper limit of normal (ULN) Albumin ≥ 2 g/dL Bilirubin ≤ 1.5 times ULN Renal Creatinine normal for age OR Creatinine clearance OR radioisotope glomerular filtration rate ≥ 70 mL/min/1.73 m^2 Other Not pregnant or nursing Negative pregnancy test Fertile patients must use effective contraception No uncontrolled infection PRIOR CONCURRENT THERAPY: Biologic therapy At least 7 days since prior biologic therapy, including immunotherapy At least 3 months since prior stem cell transplantation No evidence of active graft-vs-host disease No concurrent biologic therapy No concurrent immunotherapy Chemotherapy Recovered from prior chemotherapy At least 6 weeks since prior nitrosoureas Prior therapy with hydroxyurea allowed for up to 24 hours before initiation of study drug No other concurrent chemotherapy Endocrine therapy Concurrent hydrocortisone or other corticosteroids allowed as premedications prior to blood product transfusions in patients with prior severe allergic reactions Radiotherapy Recovered from prior radiotherapy No concurrent radiotherapy Surgery Not specified Other No other concurrent anticancer agents No other concurrent investigational drugs
Overall Study Officials:
First Name & Middle Initial & Last Name & Degree
Terzah M. Horton, MD, PhD
Organizational Affiliation
Texas Children's Cancer Center
Official's Role
Study Chair
Facility Information:
Facility Name
Stanford Cancer Center at Stanford University Medical Center
City
Stanford
State/Province
California
ZIP/Postal Code
94305
Country
United States
Facility Name
Indiana University Cancer Center
City
Indianapolis
State/Province
Indiana
ZIP/Postal Code
46202-5289
Country
United States
Facility Name
Fairview University Medical Center - University Campus
City
Minneapolis
State/Province
Minnesota
ZIP/Postal Code
55455
Country
United States
Facility Name
Mayo Clinic Cancer Center
City
Rochester
State/Province
Minnesota
ZIP/Postal Code
55905
Country
United States
Facility Name
University of Mississippi Medical Center
City
Jackson
State/Province
Mississippi
ZIP/Postal Code
39216-4505
Country
United States
Facility Name
Herbert Irving Comprehensive Cancer Center at Columbia University
City
New York
State/Province
New York
ZIP/Postal Code
10032
Country
United States
Facility Name
SUNY Upstate Medical University Hospital
City
Syracuse
State/Province
New York
ZIP/Postal Code
13210
Country
United States
Facility Name
Cincinnati Children's Hospital Medical Center
City
Cincinnati
State/Province
Ohio
ZIP/Postal Code
45229-3039
Country
United States
Facility Name
Children's Hospital of Philadelphia
City
Philadelphia
State/Province
Pennsylvania
ZIP/Postal Code
19104-9786
Country
United States
Facility Name
Children's Hospital of Pittsburgh
City
Pittsburgh
State/Province
Pennsylvania
ZIP/Postal Code
15213
Country
United States
Facility Name
St. Jude Children's Research Hospital
City
Memphis
State/Province
Tennessee
ZIP/Postal Code
38105
Country
United States
Facility Name
Simmons Comprehensive Cancer Center at University of Texas Southwestern Medical Center - Dallas
City
Dallas
State/Province
Texas
ZIP/Postal Code
75390
Country
United States
Facility Name
Baylor University Medical Center - Houston
City
Houston
State/Province
Texas
ZIP/Postal Code
77030-2399
Country
United States
Facility Name
Children's Hospital and Regional Medical Center - Seattle
City
Seattle
State/Province
Washington
ZIP/Postal Code
98105
Country
United States
Facility Name
Hospital for Sick Children
City
Toronto
State/Province
Ontario
ZIP/Postal Code
M5G 1X8
Country
Canada
Facility Name
Hopital Sainte Justine
City
Montreal
State/Province
Quebec
ZIP/Postal Code
H3T 1C5
Country
Canada

12. IPD Sharing Statement

Citations:
PubMed Identifier
17971589
Citation
Horton TM, Thompson PA, Berg SL, Adamson PC, Ingle AM, Dolan ME, Delaney SM, Hedge M, Weiss HL, Wu MF, Blaney SM; Children's Oncology Group Study. Phase I pharmacokinetic and pharmacodynamic study of temozolomide in pediatric patients with refractory or recurrent leukemia: a Children's Oncology Group Study. J Clin Oncol. 2007 Nov 1;25(31):4922-8. doi: 10.1200/JCO.2007.12.0667.
Results Reference
result
Citation
Horton TM, Dolan E, Hegde M, et al.: A phase I study of temozolomide (Temodar®) in pediatric patients with relapsed or refractory leukemia: a Children's Oncology Group study. [Abstract] Blood 106 (11): A-4455, 2005.
Results Reference
result

Learn more about this trial

Temozolomide in Treating Young Patients With Refractory or Recurrent Leukemia

We'll reach out to this number within 24 hrs